Stock comparison
Biogen
IDEXX Laboratories
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
BIIB
Biogen
Market cap
$28.61B
Sector
Healthcare
IDXX
IDEXX Laboratories
Market cap
$44.12B
Sector
Healthcare
Overall winner
IDEXX Laboratories IDXX
Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.
Fit scores by strategy
| Strategy | BIIB | IDXX | Winner |
|---|---|---|---|
| Warren Buffett | 53C | 75B | IDXX |
| Benjamin Graham | 63C | 80A | IDXX |
| Philip Fisher | 43D | 75B | IDXX |
| Peter Lynch | 21F | 71B | IDXX |
| Joel Greenblatt | 34F | 83C | IDXX |
| Charlie Munger | 48D | 87A | IDXX |
| Terry Smith | 49D | 84A | IDXX |
Side-by-side metrics
| Metric | BIIB | IDXX |
|---|---|---|
| Market cap | $28.61B | $44.12B |
| P/E (TTM) | 21.2x | 39.0x |
| EV/EBIT | 17.3x | 31.6x |
| ROIC (TTM) | 5.44% | 40.66% |
| Gross margin | 69.77% | 62.05% |
| Net margin | 13.92% | 24.63% |
| Revenue CAGR 5y | -2.78% | 7.56% |
| EPS CAGR 5y | -4.05% | 10.79% |
| Debt / Equity | 0.4x | 0.7x |
| Dividend yield | 0.0% | 0.0% |
Where each one wins
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
BIIB leads on
- Debt / Equity0.4xvs 0.7x+49%
- P/E (TTM)21.2xvs 39.0x+46%
- EV/EBIT17.3xvs 31.6x+45%
- Gross margin69.77%vs 62.05%+11%
IDXX leads on
- EPS CAGR 5y10.79%vs -4.05%+137%
- Revenue CAGR 5y7.56%vs -2.78%+137%
- ROIC (TTM)40.66%vs 5.44%+87%
- Net margin24.63%vs 13.92%+43%
Related on invest-like
Key terms in this analysis
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.